Detecting Parkinson Disease at Early Stages With Alpha-Synuclein Amplification Assay: Russell Lebovitz, MD, PhD

Neurology Live, May 11, 2023

In 2019, the FDA granted Amprion a Breakthrough Device Designation for use of its SYNTap Biomarker Test in assisting for the diagnosis of Parkinson Disease (PD), becoming commercially available years later in 2021. The test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to help with the diagnosis of synucleinopathies such as in PD, Lewy Body dementia (LBD), and Alzheimer Disease (AD) with the Lewy Body variant...READ MORE

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.


Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.